Because death receptors (DR), including CD95 (Fas/APO1), DR3, DR6, TNF-R1, and TNF-related apoptosis-inducing factor (TRAIL)-R1/DR4 and TRAIL-R2/DR5, depending on their expression, have the ability to trigger apoptosis in most tumor cells, strategies to activate death signaling via DR agonists or agonistic antibodies have strong therapeutic potential against cancer. This evidence concerns the gene FAS and cancer.